Intravitreal Dexamethasone Implant in the Treatment of Non-Infectious Uveitic Macular Edema
Medical hypothesis discovery and innovation in ophthalmology,
Vol. 7 No. 4 (2018),
1 December 2018
,
Page 169-175
Abstract
Macular Edema (ME) is a common complication, leading to severe vision loss in patients with Non-Infectious Uveitis (NIU). The treatment of uveitic ME is still very challenging for many ophthalmologists. Various agents, such as corticosteroids, anti-vascular endothelial growth factors, and immune-modulators, have been used for combatting uveitic ME. However, there is not enough evidence to support the efficacy of any of these agents. Intravitreal Dexamethasone Implant (IDI) (Ozurdex; Allergan Inc, Irvine, CA) is a widely administered corticosteroid for the long-term management of uveitic ME in certain cases. Ophthalmic implant is made up of a biodegradable copolymer that contains glycolic acid and lactic acid. Recent studies have demonstrated that dexamethasone implant effectively improves uveitis-related ME. The authors suggest that this effect could be sustained for at least six months with close monitoring and re-treatment, as needed. The current study reviewed major clinical studies about IDI in eyes with NIU and briefly overviewed their results.References
de Smet MD, Taylor SR, Bodaghi B, Miserocchi E, Murray PI, Pleyer U, et al. Understanding uveitis: the impact of research on visual outcomes. Prog Retin Eye Res. 2011;30(6):452-70. doi: 10.1016/j.preteyeres.2011.06.005 pmid: 21807112
Bodaghi B, Cassoux N, Wechsler B, Hannouche D, Fardeau C, Papo T, et al. Chronic severe uveitis: etiology and visual outcome in 927 patients from a single center. Medicine (Baltimore). 2001;80(4):263-70. pmid: 11470987
Rothova A, Suttorp-van Schulten MS, Frits Treffers W, Kijlstra A. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol. 1996;80(4):332-6. pmid: 8703885
Darrell RW, Wagener HP, Kurland LT. Epidemiology of uveitis. Incidence and prevalence in a small urban community. Arch Ophthalmol. 1962;68:502-14. pmid: 13883604
Suttorp-Schulten MS, Rothova A. The possible impact of uveitis in blindness: a literature survey. Br J Ophthalmol. 1996;80(9):844-8. pmid: 8962842
Goldhardt R, Rosen BS. Uveitic Macular Edema: Treatment Update. Curr Ophthalmol Rep. 2016;4(1):30-7. doi: 10.1007/s40135-016-0090-3 pmid: 27347446
de Smet MD, Julian K. The role of steroids in the management of uveitic macular edema. Eur J Ophthalmol. 2011;21 Suppl 6:S51-5. doi: 10.5301/EJO.2010.6056 pmid: 23264329
Freeman G, Matos K, Pavesio CE. Cystoid macular oedema in uveitis: an unsolved problem. Eye (Lond). 2001;15(Pt 1):12-7. doi: 10.1038/eye.2001.5 pmid: 11318279
Durrani OM, Meads CA, Murray PI. Uveitis: a potentially blinding disease. Ophthalmologica. 2004;218(4):223-36. doi: 10.1159/000078612 pmid: 15258410
Forrester JV. Uveitis: pathogenesis. Lancet. 1991;338(8781):1498-501. pmid: 1683927
Dick AD. Immune mechanisms of uveitis: insights into disease pathogenesis and treatment. Int Ophthalmol Clin. 2000;40(2):1-18. pmid: 10791254
Cordero Coma M, Sobrin L, Onal S, Christen W, Foster CS. Intravitreal bevacizumab for treatment of uveitic macular edema. Ophthalmology. 2007;114(8):1574-9 e1. doi: 10.1016/j.ophtha.2006.11.028 pmid: 17363060
de Smet MD, Okada AA. Cystoid macular edema in uveitis. Dev Ophthalmol. 2010;47:136-47. doi: 10.1159/000320077 pmid: 20703047
Ossewaarde-van Norel A, Rothova A. Clinical review: Update on treatment of inflammatory macular edema. Ocul Immunol Inflamm. 2011;19(1):75-83. doi: 10.3109/09273948.2010.509530 pmid: 21034302
Catier A, Tadayoni R, Paques M, Erginay A, Haouchine B, Gaudric A, et al. Characterization of macular edema from various etiologies by optical coherence tomography. Am J Ophthalmol. 2005;140(2):200-6. doi: 10.1016/j.ajo.2005.02.053 pmid: 15992752
Markomichelakis NN, Halkiadakis I, Pantelia E, Peponis V, Patelis A, Theodossiadis P, et al. Patterns of macular edema in patients with uveitis: qualitative and quantitative assessment using optical coherence tomography. Ophthalmology. 2004;111(5):946-53. doi: 10.1016/j.ophtha.2003.08.037 pmid: 15121373
Iannetti L, Accorinti M, Liverani M, Caggiano C, Abdulaziz R, Pivetti-Pezzi P. Optical coherence tomography for classification and clinical evaluation of macular edema in patients with uveitis. Ocul Immunol Inflamm. 2008;16(4):155-60. doi: 10.1080/09273940802187466 pmid: 18716950
Karim R, Sykakis E, Lightman S, Fraser-Bell S. Interventions for the treatment of uveitic macular edema: a systematic review and meta-analysis. Clin Ophthalmol. 2013;7:1109-44. doi: 10.2147/OPTH.S40268 pmid: 23807831
Venkatesh P, Kumar CS, Abbas Z, Garg S. Comparison of the efficacy and safety of different methods of posterior subtenon injection. Ocul Immunol Inflamm. 2008;16(5):217-23. doi: 10.1080/09273940802209153 pmid: 19065416
Winterhalter S, Behrens UD, Salchow D, Joussen AM, Pleyer U. Dexamethasone implants in paediatric patients with noninfectious intermediate or posterior uveitis: first prospective exploratory case series. BMC Ophthalmol. 2017;17(1):252. doi: 10.1186/s12886-017-0648-3 pmid: 29246154
Sella R, Oray M, Friling R, Umar L, Tugal-Tutkun I, Kramer M. Dexamethasone intravitreal implant (Ozurdex(R)) for pediatric uveitis. Graefes Arch Clin Exp Ophthalmol. 2015;253(10):1777-82. doi: 10.1007/s00417-015-3124-x pmid: 26228441
Sampat KM, Garg SJ. Complications of intravitreal injections. Curr Opin Ophthalmol. 2010;21(3):178-83. doi: 10.1097/ICU.0b013e328338679a pmid: 20375895
Fassbender Adeniran JM, Jusufbegovic D, Schaal S. Common and Rare Ocular Side-effects of the Dexamethasone Implant. Ocul Immunol Inflamm. 2017;25(6):834-40. doi: 10.1080/09273948.2016.1184284 pmid: 27379861
Lowder C, Belfort R, Jr., Lightman S, Foster CS, Robinson MR, Schiffman RM, et al. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol. 2011;129(5):545-53. doi: 10.1001/archophthalmol.2010.339 pmid: 21220619
Ratra D, Barh A, Banerjee M, Ratra V, Biswas J. Safety and Efficacy of Intravitreal Dexamethasone Implant for Refractory Uveitic Macular Edema in Adults and Children. Ocul Immunol Inflamm. 2018:1-7. doi: 10.1080/09273948.2018.1424342 pmid: 29394119
Haller JA, Dugel P, Weinberg DV, Chou C, Whitcup SM. Evaluation of the safety and performance of an applicator for a novel intravitreal dexamethasone drug delivery system for the treatment of macular edema. Retina. 2009;29(1):46-51. doi: 10.1097/IAE.0b013e318188c814 pmid: 18827732
Chang-Lin JE, Attar M, Acheampong AA, Robinson MR, Whitcup SM, Kuppermann BD, et al. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci. 2011;52(1):80-6. doi: 10.1167/iovs.10-5285 pmid: 20702826
Kuppermann BD, Blumenkranz MS, Haller JA, Williams GA, Weinberg DV, Chou C, et al. Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch Ophthalmol. 2007;125(3):309-17. doi: 10.1001/archopht.125.3.309 pmid: 17353400
London NJ, Chiang A, Haller JA. The dexamethasone drug delivery system: indications and evidence. Adv Ther. 2011;28(5):351-66. doi: 10.1007/s12325-011-0019-z pmid: 21494891
Nobre-Cardoso J, Champion E, Darugar A, Fel A, Lehoang P, Bodaghi B. Treatment of Non-infectious Uveitic Macular Edema with the Intravitreal Dexamethasone Implant. Ocul Immunol Inflamm. 2017;25(4):447-54. doi: 10.3109/09273948.2015.1132738 pmid: 27003221
Adan A, Pelegrin L, Rey A, Llorenc V, Mesquida M, Molins B, et al. Dexamethasone intravitreal implant for treatment of uveitic persistent cystoid macular edema in vitrectomized patients. Retina. 2013;33(7):1435-40. doi: 10.1097/IAE.0b013e31827e247b pmid: 23514796
Pohlmann D, Vom Brocke GA, Winterhalter S, Steurer T, Thees S, Pleyer U. Dexamethasone Inserts in Noninfectious Uveitis: A Single-Center Experience. Ophthalmology. 2018;125(7):1088-99. doi: 10.1016/j.ophtha.2017.12.038 pmid: 29459041
Yalcinbayir O, Caliskan E, Ucan Gunduz G, Gelisken O, Kaderli B, Yucel AA. Efficacy of Dexamethasone Implants in Uveitic Macular Edema in Cases with Behcet Disease. Ophthalmologica. 2018:1-5. doi: 10.1159/000490674 pmid: 30244248
Tsang AC, Virgili G, Abtahi M, Gottlieb CC. Intravitreal Dexamethasone Implant for the Treatment of Macular Edema in Chronic Non-infectious Uveitis. Ocul Immunol Inflamm. 2017;25(5):685-92. doi: 10.3109/09273948.2016.1160130 pmid: 27191685
Khurana RN, Porco TC. Efficacy and Safety of Dexamethasone Intravitreal Implant for Persistent Uveitic Cystoid Macular Edema. Retina. 2015;35(8):1640-6. doi: 10.1097/IAE.0000000000000515 pmid: 25741813
Bansal P, Agarwal A, Gupta V, Singh R, Gupta A. Spectral domain optical coherence tomography changes following intravitreal dexamethasone implant, Ozurdex(R) in patients with uveitic cystoid macular edema. Indian J Ophthalmol. 2015;63(5):416-22. doi: 10.4103/0301-4738.159870 pmid: 26139803
Pleyer U, Klamann M, Laurent TJ, Manz M, Hazirolan D, Winterhalter S, et al. Fast and Successful Management of Intraocular Inflammation with a Single Intravitreal Dexamethasone Implant. Ophthalmologica. 2014. doi: 10.1159/000368987 pmid: 25428335
Cao JH, Mulvahill M, Zhang L, Joondeph BC, Dacey MS. Dexamethasone intravitreal implant in the treatment of persistent uveitic macular edema in the absence of active inflammation. Ophthalmology. 2014;121(10):1871-6. doi: 10.1016/j.ophtha.2014.04. 012 pmid: 24907061
Zarranz-Ventura J, Carreno E, Johnston RL, Mohammed Q, Ross AH, Barker C, et al. Multicenter study of intravitreal dexamethasone implant in noninfectious uveitis: indications, outcomes, and reinjection frequency. Am J Ophthalmol. 2014;158(6):1136-45 e5. doi: 10.1016/j.ajo.2014.09.003 pmid: 25217856
Wiechens B, Nolle B, Reichelt JA. Pars-plana vitrectomy in cystoid macular edema associated with intermediate uveitis. Graefes Arch Clin Exp Ophthalmol. 2001;239(7):474-81. pmid: 11521690
Heiligenhaus A, Bornfeld N, Wessing A. Long-term results of pars plana vitrectomy in the management of intermediate uveitis. Curr Opin Ophthalmol. 1996;7(3):77-9. pmid: 10163465
Pelegrin L, de la Maza MS, Molins B, Rios J, Adan A. Long-term evaluation of dexamethasone intravitreal implant in vitrectomized and non-vitrectomized eyes with macular edema secondary to non-infectious uveitis. Eye (Lond). 2015;29(7):943-50. doi: 10.1038/eye.2015.73 pmid: 25998942
- Abstract Viewed: 1573 times
- Full Text PDF Downloaded: 1105 times